It is going to be super interesting what they decided to do. My bet is they go for a limited approval and in some ways that is the best outcome for Cogstate as it will likely require ongoing clinical monitoring of approved patients and this will embed Cognigram in to the clinical process beyond a triage tool. In my thinking if the FDA were going to go with an outright no, they have had numerous opportunities to do this already, why would they not have taken them. Either way Cogstate is priced on the basis that there is a rejection and if that were to be the outcome we may well have a bit of a swoon, but it would be a very buyable swoon in my opinion.
CGS Price at posting:
95.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)